However, we observed up-regulation of IL-17 complex and TH17 gene signatures in nonlesional PSO and AD samples, as well as up-regulation of the IL-17 complex signature in nonlesional DLE as compared to control samples, suggesting that IL-17 targeting might be appropriate to prevent the emergence of typical skin lesions in all three diseases as well as to treat established plaques in lesional PSO. The gene discussed is IL17A; the disease is Alzheimer disease.